Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 1.07% is 102% above its 2-year average of -68.48%, near the high end of its 2-year range (-641.30%–29.30%).
100.66% above its 12-month average of -161.15%.
Reported quarterly EBITDA margin; no daily interpolation. Q4 FY2014 (2014-12-31): -641.30%.
EBITDA MARGIN
1.07%
EBITDA MARGIN AVG TTM
-161.15%
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+100.66%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$7.50M
EBITDA Margin
-3822.36%
TTM Avg
-2499.82%
3Y Avg
-7123.25%
5Y Avg
-7123.25%
Market Cap
$7.25M
EBITDA Margin
-0.29%
TTM Avg
-74.83%
3Y Avg
-125.41%
5Y Avg
-344.12%
Market Cap
$7.24M
EBITDA Margin
-1839.87%
TTM Avg
-1245.27%
3Y Avg
-1681.64%
5Y Avg
-1341.06%
Market Cap
$7.72M
EBITDA Margin
-144973.96%
TTM Avg
-73136.05%
3Y Avg
-36678.29%
5Y Avg
-29395.87%
Market Cap
$7.07M
EBITDA Margin
3.56%
TTM Avg
3.56%
3Y Avg
3.56%
5Y Avg
3.56%
Market Cap
$7.92M
EBITDA Margin
-638.49%
TTM Avg
-11234.29%
3Y Avg
-10030.31%
5Y Avg
-9704.67%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Skye Bioscience, Inc. (SKYE) | $7.45M | 1.07% | -161.15% | N/A | N/A |
| Mangoceuticals, Inc. (MGRX)vs › | $7.50M | -3822.36% | -2499.82% | -7123.25% | -7123.25% |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.25M | -0.29% | -74.83% | -125.41% | -344.12% |
| Quince Therapeutics, Inc. (QNCX)vs › | $7.57M | N/A | N/A | N/A | N/A |
| Longeveron Inc. (LGVN)vs › | $7.24M | -1839.87% | -1245.27% | -1681.64% | -1341.06% |
| ENDRA Life Sciences Inc. (NDRA)vs › | $7.72M | -144973.96% | -73136.05% | -36678.29% | -29395.87% |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $6.91M | N/A | N/A | N/A | N/A |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.07M | 3.56% | 3.56% | 3.56% | 3.56% |
| Traws Pharma, Inc. (TRAW)vs › | $7.92M | -638.49% | -11234.29% | -10030.31% | -9704.67% |
| KALA BIO, Inc. (KALA)vs › | $7.00M | -2068.24% | -1510.83% | -1474.78% | -1474.78% |
Gross Margin
0.0%
EBITDA Margin
1.1%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2014-12-31 | -641.30% |
| 2014-06-30 | 10.07% |
| 2014-04-30 | -15.18% |
| 2014-01-31 | 1.80% |
| 2013-10-31 | -3.50% |
| 2013-07-31 | 5.04% |
| 2013-04-30 | 6.85% |
| 2013-01-31 | -9.46% |
| 2012-10-31 | 29.30% |
